EMEA-002562-PIP01-19

Key facts

Active substance
Autologous CD34+ haematopoietic stem cells transduced ex vivo with a lentiviral vector encoding for the human Beta 2 Integrin/CD18 gene
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0106/2020
PIP number
EMEA-002562-PIP01-19
Pharmaceutical form(s)
Dispersion for infusion
Condition(s) / indication(s)
Treatment of leukocyte adhesion deficiency type I
Route(s) of administration
Intravenous use
Contact for public enquiries
Rocket Pharmaceuticals, Inc.

E-mail: sk@rocketpharma.com
Tel.: +1 6465815229

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating